ICU Medical Inc (ICUI) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges

GuruFocus News

Fri, February 20, 2026 at 2:04 PM GMT+9 4 min read

In this article:

ICUI

-1.25%

This article first appeared on GuruFocus.

**Q4 Revenue:** $536 million, 2% organic growth, -14% reported.

**Full Year 2025 Revenue Growth:** 5% organic growth.

**Gross Margin:** Above 40% for Q4.

**Q4 EBITDA:** $98 million.

**Q4 EPS:** $1.91.

**Net Debt:** Just below $1 billion.

**Consumables Business Q4 Growth:** 6% reported, 5% organic.

**IV Systems Business Q4 Growth:** 3% reported, 1% organic.

**Vital Care Q4 Performance:** Decreased 6% organic, 35% reported.

**Adjusted Gross Margin Q4:** 40.5%.

**Adjusted SG&A Expense Q4:** $113 million.

**Adjusted R&D Expense Q4:** $21 million.

**Adjusted Operating Expenses Q4:** $134 million, 25% of revenue.

**Adjusted EBITDA Q4:** $98 million, 7% decrease from last year.

**Adjusted EPS Q4:** $1.91, 9% decline from last year.

**Free Cash Flow Q4:** $44 million.

**Debt at End of Q4:** $1.3 billion.

**2026 Revenue Growth Guidance:** Low- to mid-single-digit organic growth.

**2026 Adjusted Gross Margin Guidance:** Around 41%.

**2026 Adjusted EBITDA Guidance:** $400 million to $430 million.

**2026 Adjusted EPS Guidance:** $7.75 to $8.45 per share.

**2026 Free Cash Flow Expectation:** Improvement relative to 2025.

**Net Leverage Ratio at End of 2025:** Just under 2.5 times.

Warning! GuruFocus has detected 7 Warning Signs with ICUI.

Is ICUI fairly valued? Test your thesis with our free DCF calculator.

Release Date: February 19, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

ICU Medical Inc (NASDAQ:ICUI) reported a strong Q4 revenue of $536 million, achieving 2% organic growth and maintaining gross margins above 40%.

The Consumables business experienced a record quarter with 6% reported growth and 5% organic growth, driven by high-single-digit growth in infusion consumables, oncology, and tracheostomy product lines.

The company successfully closed the FDA warning letter received by Smiths Medical, validating their operational improvements and opening up more strategic choices.

ICU Medical Inc (NASDAQ:ICUI) has completed the manufacturing integration of two large legacy Smiths Medical sites, which is expected to lead to future synergies and cost savings.

The company has a strong cash generation, allowing it to repay additional principal, reducing net debt to just below $1 billion.

Negative Points

The reported revenue showed a decline of 14% due to the deconsolidation of the IV Solutions business following the creation of the Otsuka-ICU Medical JV.

Adjusted EBITDA for Q4 decreased by 7% year-over-year, impacted by the deconsolidation of the IV Solutions business and tariffs, resulting in a $25 million negative impact.

Vital Care segment saw a 6% organic decrease and a 35% reported decrease due to the deconsolidation of IV Solutions, impacting overall company growth rates.

The company faces ongoing challenges with tariffs, which are expected to impact gross margins by approximately 2% of revenue in 2026.

Despite improvements, the integration of Smiths Medical has been bumpier and taken longer than expected, with the 2026 EBITDA guidance still short of the original $500 million target.

 






Story Continues  

Q & A Highlights

Q: Can you discuss the current environment for your Systems business, particularly regarding customer decisions and any potential pauses? A: Vivek Jain, CEO: The capital environment remains stable, with deals getting done. There has been a historical backup in refresh cycles, but improvements are meaningful to our P&L. Most of the pump business in the US is focused on Duo and Solo products, while internationally, the 60 continues to be placed.

Q: Are the pending clearances for syringe and ambulatory pumps affecting Infusion System sales? A: Vivek Jain, CEO: No, the syringe business performed well last year, and customers interested in the platform are engaging with us. We are pleased with the regulatory response and are working through the normal back-and-forth process.

Q: What is the outlook for Consumables growth, and have you noticed any changes in hospital utilization volumes? A: Vivek Jain, CEO: Our guidance remains mid-single-digit growth, consistent with previous years. While growth rates were lower in the back half of last year, we haven’t seen any impact on underlying demand or utilization.

Q: How are you addressing the impact of tariffs, and are there any changes in geographic exposure? A: Brian Bonnell, CFO: We have made structural changes to mitigate tariffs, which helped in Q4. While there is more work to be done, benefits may not be realized until later in the year due to the complexity of these efforts.

Q: Can you provide insights into the potential sale of the Vital Care business and its impact on earnings? A: Vivek Jain, CEO: Vital Care is likely below the corporate gross margin. We aim to find strategic outcomes that are EPS neutral, similar to the solutions JV, while improving the organic profile of the business.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Terms and Privacy Policy

Privacy Dashboard

More Info